Quris-AI's Bio-AI Platform Integrated by Merck KGaA
Quris-AI's Bio-AI Platform Integrated by Merck KGaA, Darmstadt, Germany for Preclinical Small Molecule Drug Safety Evaluation
BOSTON and TEL-AVIV, Israel. Quris-AI, an artificial intelligence (AI) innovator disrupting the pharmaceutical arena, today announced that Merck KGaA, Darmstadt, Germany, a leading science and technology company, has adopted Quris’ Bio-AI clinical prediction platform as part of Merck KGaA, Darmstadt, Germany’s drug development pipeline.
Selected preclinical small molecule candidates will now be tested through the Quris-AI platform prior to initiating clinical trials. This follows a successful two-year validation study with Merck KGaA, Darmstadt, Germany, in which Quris-AI delivered a significantly higher accuracy in detecting drug-induced liver injury (DILI) compared to existing safety prediction approaches, potentially reducing reliance on animal testing.
“This collaboration is a pivotal achievement for Quris-AI, providing important validation of the value that its platform brings to drug discovery,” said Prof. Robert S. Langer, Moderna Co-Founder and Former Chairman of the FDA Science Board, who currently serves on the Quris-AI Scientific Advisory Board. “Quris-AI is broadly recognized as a leader in harnessing AI to revolutionize drug development and is uniquely positioned to address the FDA Modernization Acts 2.0 and now 3.0, which push to use AI, organ-on-chip, and other advanced technologies to replace antiquated animal testing.”
Quris-AI’s drug safety prediction platform integrates advanced AI, machine learning, generative models, patient-on-chip technology, and proprietary data to predict potential drug- induced toxicities better. It is expected to improve safety predictions, speed up time to market, and ultimately enhance success rates.
Quris-AI, the world’s first Bio-AI clinical prediction platform, ensures the safety of new drugs. The company is revolutionizing the drug development process, pioneering clinical trials on chips – testing thousands of novel drug candidates on hundreds of miniaturized “patients-on-a-chip.” Its fully automated, self-training AI platform accurately predicts clinical safety and efficacy for novel drugs faster and more cost-effectively than ever before – all while minimizing animal testing. Dual-headquartered in Boston and Israel and backed by strategic biotech and big data investors, Quris-AI is led by a proven team of AI and medical research powerhouses.
